Press area
The latest press information about third party audits is available for you to download on these pages. Publication for editorial and scientific purposes is free of charge; please send us brief notification or a specimen copy.
Contact:
blue inspection body GmbH
Hafenweg 18-20
D-48155 Münster
Personal contact:
Dr. Stefan Kettelhoit
Phone: +49(0)251 625620-40
info@blue-inspection.com
Agency contact:
Advertising & Public Relations
co-operate
Wegener & Rieke GmbH
Zumsandestr. 32
D-48145 Münster
Personal contact:
Christian Rieke
Phone: +49 (0)251 3222611
dialog@co-operate.net
blue inspection body celebrates 50 GMP audits
Münster (Germany), 20 November 2009.Two years after founding the company and just 18 months after gaining the accreditation blue inspection body GmbH announced today the successful execution of its 50th GMP audit. Further audit trips to China, India, Israel and various European countries have been scheduled already, meaning that in the first quarter 2010 the 75th audit is targeted to be completed. Blue, as a privately organised inspection body, has thereby set a new benchmark concerning quality and amount of GMP audits for active pharmaceutical ingredients (APIs) in no time at all. The European Directorate for the Quality of Medicines & HealthCare (EDQM) for example, conducted just 28 inspections during 2008.
Blue inspection body GmbH globally examines the Good Manufacturing Practice (GMP) compliant manufacturing of APIs and medicinal products on behalf of pharmaceutical companies. These so called third party audits are used by the pharmaceutical industry to qualify suppliers appropriately, according to regulatory and legal requirements. Nowadays suppliers are usually located outside Europe mostly in Asian countries.
"With the accreditation of GMP audits and the application of quality assurance to third party audits we have broken completely new grounds mid of 2008;" illustrates Dr. Stefan Kettelhoit, managing director of blue inspection body GmbH (www.blue-inspection.com). "At that point in time the proposal for amending the European pharmaceutical directive 2001/83/EC was not published at all and thereby the term accredited was vastly unknown in the field of GMP audits."
(approx. 1.450 Characters)
Download (Format: DOC, 41.50 KB)
